3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Colorectal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Solid Tumors
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
aldesleukin
26
Sunitinib
25
Interferon-alpha
21
Everolimus
18
Sorafenib
16
Cyclophosphamide
16
Filgrastim
13
Bevacizumab
13
Nivolumab
11
Gemcitabine
11
Interleukin-2
10
Axitinib
10
fludarabine phosphate
9
Gene Expression Profiling
9
temsirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Doxorubicin
8
pembrolizumab
7
Radiotherapy
6
Radiosurgery
6
Polymerase Chain Reaction
6
Ipilimumab
6
Carboplatin
6
sargramostim
5
Ifosfamide
5
Fluorouracil
5
Erlotinib Hydrochloride
5
Capecitabine
5
Bortezomib
5
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Kidney Neoplasms
×
CB-839
×
Clear all
NCT03428217
2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2
Completed
444 enrolled
15 charts